Metronidazole-induced encephalopathy with concurrent peripheral neuropathy in Crohn’s disease: a case report

Article information

Kosin Med J. 2026;.kmj.25.144
Publication date (electronic) : 2026 June 22
doi : https://doi.org/10.7180/kmj.25.144
Department of Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
Corresponding Author: Seung Hyun Lee, MD Department of Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, Korea Tel: +82-51-990-6462 Fax: +82-51-246-6093 E-mail: gscrslsh@kosin.ac.kr
Received 2025 December 7; Revised 2026 January 18; Accepted 2026 March 6.

Abstract

Metronidazole, which is often used in inflammatory bowel disease, can rarely cause encephalopathy and peripheral neuropathy. This report describes a patient with Crohn’s disease who developed metronidazole-induced encephalopathy accompanied by sensory-predominant peripheral neuropathy after repeated exposure. The patient presented with slurred speech, acute dysarthria, and peripheral numbness after repeated metronidazole exposure. Brain magnetic resonance imaging showed symmetric dentate-nucleus hyperintensity, supporting a diagnosis of metronidazole-induced encephalopathy. Slurred speech and dysarthria improved rapidly after discontinuation of metronidazole, whereas the peripheral neuropathy recovered more slowly. This case highlights the importance of recognizing the features of metronidazole-induced encephalopathy and promptly discontinuing metronidazole when it is suspected.

Introduction

Metronidazole is widely prescribed for anaerobic infections and for inflammatory bowel disease [1]. Although generally safe, a recognized adverse effect that can involve both central and peripheral nervous systems should be noted [2]. Typical central nervous system (CNS) manifestations include cerebellar dysfunction and encephalopathy, with magnetic resonance imaging (MRI) often demonstrating symmetric dentate-nucleus hyperintensity on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences. CNS symptoms typically improve rapidly after drug cessation, whereas peripheral neuropathy tends to recover more slowly [3]. This report describes a patient with postoperative Crohn’s disease who developed metronidazole-induced encephalopathy and sensory-predominant peripheral neuropathy.

Case

Ethical statements: This report was approved by the Institutional Review Board (IRB) of Kosin University Gospel Hospital (IRB No. 2025-11-017). The IRB waived the requirement for informed consent.

A 34-year-old male patient with a 20-year history of Crohn’s disease, who had previously undergone a right hemicolectomy, was transferred to the colorectal surgery department with a duodeno-enteric fistula. His medical history included treatment with adalimumab, ustekinumab, azathioprine, 5-aminosalicylic acid, intravenous steroids, and upadacitinib in sequence. The patient underwent small bowel resection, ileocolic anastomosis, and primary closure of a duodenal fistula. The resected specimen included the previous ileocolic anastomosis site and the duodeno-enteric fistula site at ileum. The postoperative course was uneventful, and the patient was discharged on postoperative day 12.

Two days after discharge, he presented to the emergency department with abdominal pain and severe diarrhea. Physical examination revealed tenderness in the right upper and lower quadrants. Laboratory tests showed a white blood cell count of 13,740/µL and a high-sensitivity C-reactive protein level of 3.8 mg/dL. Computed tomography (CT) demonstrated aggravated inflammation and an abscess in the upper mid-abdomen with sealed perforation. The operative wound showed a 7 cm dehiscence with seroma formation. The patient was readmitted and treated with intravenous ciprofloxacin and metronidazole. Upper gastrointestinal with gastrografin showed no evidence of leakage from the previous duodenal fistula site. His condition gradually improved, and follow-up CT on hospital day 16 revealed decreased abscess size and inflammation. On hospital day 17, antibiotics were switched from intravenous to oral ciprofloxacin and metronidazole, and he was discharged on hospital day 20.

However, 2 days after the discharge, the patient returned to the emergency department with fever, chills, and wound discharge. Examination revealed aggravated wound dehiscence, redness, and purulent oozing with a fecal odor. CT showed increased multifocal postoperative fluid collections and abscesses at anterior abdominal wall. Intravenous ciprofloxacin (400 mg) and metronidazole (500 mg, three times daily) were resumed. On hospital day 3, the patient complained of tingling sensations and numbness in both hands and feet, which he noted had started mildly before his second discharge and had progressively worsened after readmission.

Initially, Crohn’s disease-related vascular neuropathy was suspected, and gabapentin 75 mg orally three times daily was initiated for symptomatic relief. By hospital day 4, the symptoms intensified to a pain score of 4 on the numeric rating scale. On hospital day 5, he suddenly developed dysarthria with slurred speech but no other neurological symptoms.

Neurologic assessment was performed at the onset of dysarthria. No formal quantitative ataxia scale was applied; however, gait and coordination were preserved. There was no nystagmus, and the finger-to-nose test was normal. Motor strength was grade 5/5 on the Medical Research Council scale in all extremities, deep tendon reflexes were 2+ and symmetric, and sensory modalities including light touch, pinprick, and proprioception were intact.

The likelihood of an adverse drug reaction was assessed using the Naranjo Adverse Drug Reaction Probability Scale, yielding a score of 9, indicating a “definite” adverse drug reaction [4]. MRI diffusion and FLAIR images demonstrated bilateral symmetric dentate-nucleus T2 hyperintensity, suggesting metronidazole-induced encephalopathy (Fig. 1).

Fig. 1.

Patient’s magnetic resonance imaging showing symmetric T2 hyperintensity of the cerebellar dentate nucleus.

Metronidazole was immediately discontinued and replaced with piperacillin-tazobactam (4.5 g three times daily, IV). Dysarthria improved markedly the next morning and completely resolved within 2 days. Tingling sensations in the hands subsided within 3 days. Additional investigations, including serum protein electrophoresis, immunofixation, and diabetes screening, were all negative.

However, paresthesia in both feet persisted, prompting further neurophysiologic evaluation. Nerve conduction studies revealed decreased amplitudes of distal sensory nerves compared with age-matched norms. In addition, somatosensory evoked potential studies of the tibial nerve demonstrated bilateral and symmetric prolongation of the L3-popliteal fossa interpeak latencies with preserved cortical P37 latencies. These findings indicate involvement of the peripheral sensory pathways without evidence of central sensory conduction abnormalities and were consistent with antibiotic-induced peripheral neuropathy.

For symptom management, pregabalin was initially started at 75 mg twice daily but was later increased to 150 mg twice daily due to inadequate symptom control. Symptoms gradually improved from hospital day 15, with tramadol required for residual neuropathic pain until approximately hospital day 28. With clinical improvement, the patient was transferred to the gastroenterology department for Crohn’s disease management.

Discussion

Metronidazole is indispensable for anaerobic coverage and frequently is prescribed in Crohn’s disease-related infections and Clostridioides difficile infections across surgical, gastroenterology, and infectious diseases [5,6]. Yet, side effects involving both central encephalopathy and peripheral neuropathy remain under-recognized in routine clinical practice.

Metronidazole-induced encephalopathy is a rare toxic encephalopathy manifested by ataxia, dysarthria, vision disorders, seizure, and even change in mental status [2]. Although reversibility is common, severe or even fatal outcomes have been reported, highlighting the importance of early recognition and cessation [3,7].

MRI shows a striking neuro-radiologic signature of symmetric T2/FLAIR hyperintensity of the cerebellar dentate nuclei, with variable involvement of the splenium, midbrain, or cerebral white matter [5,8], as was observed in the present case. While dentate-predominant lesions are the hallmark, atypical or asymmetric involvement, including supratentorial white matter, has been described. This spectrum can prevent missed diagnoses when the canonical pattern is incomplete [5,9]. Hypotheses include free-radical-mediated injury, axonal degeneration, and interference with thiamine metabolism, which together provide a coherent framework for concurrent central and distal sensory nerve involvement, though definitive causal pathways remain to be proven [10]. Some cases have involved normal MRI findings with no cerebellar abnormalities, despite the involvement of the CNS [11,12].

Reported duration of metronidazole usage inducing encephalopathy ranges from 2 days [13] and to 8 years [14]. Goolsby et al. [15] showed that encephalopathy generally appeared after 4 weeks and with a cumulative dose greater than 42 g. Sorensen et al. [6] reported accumulative doses ranging from 5 to 2,000 g, with an average of 125.7 g. In the present case, the total amount of metronidazole administered was 70,500 mg over 48 days, both orally and intravenously (Table 1).

Metronidazole treatment history in the present case

Peripheral neuropathy can be depicted as tingling sensation, pain, hypoesthesia, numbness, or paresthesia [2]. Peripheral neuropathy during prolonged or repeated exposure is uncommon. Such pain is typically dependent on treatment duration and more prominent in the lower extremities, symptoms of which might be overlooked in busy clinical settings [9,16]. Proactive screening for sensory complaints in patients receiving an extended course of metronidazole is important for proper diagnosis [9].

Peripheral neuropathy linked to metronidazole is usually a sensory-predominant polyneuropathy characterized by distal numbness, reduced tactile sensation, and neuropathic pain, most often in the feet and lower legs [9,17]. In contrast to the typically rapid recovery of encephalopathy symptoms after discontinuation, peripheral neuropathic symptoms can improve more gradually and persist despite medication cessation [3,9,13,17,18]. In this case, peripheral neuropathy developed prior to encephalopathy. Dysarthria improved rapidly after metronidazole discontinuation, while peripheral neuropathy demonstrated gradual recovery over time.

Beyond exposure metrics, host factors also appear to shape risk. A large, nested case-control study using Ontario administrative data found metronidazole to be associated with increased odds of central and peripheral neurologic events; patients with liver disease, renal disease, alcohol use, or neurotropic medication exposure were over-represented among cases [19]. Consistent signals emerge from more recent risk-factor analyses that identify liver cirrhosis, chronic kidney disease, intravenous administration, and lower body weight as potential risk amplifiers, supporting the need for close monitoring and dose vigilance in vulnerable populations [2]. The body mass index of the present patient was 16.51 kg/m2 at onset of neuropathy and subsequently decreased by more than 4 kg, which suggests a possible susceptibility to metronidazole-induced encephalopathy.

For patients requiring metronidazole for a longer duration, clinicians should (1) counsel the patient about early sensory symptoms, (2) monitor for cerebellar signs (dysarthria, gait instability) and ocular disturbances, and (3) switch promptly to alternative anaerobic coverage if suspected. Early withdrawal is associated with rapid reversal of encephalopathic features, while supportive management might be needed for lingering peripheral neuropathy [13,17,18]. This case adds to this literature by illustrating the dual-system pattern—rapidly reversible encephalopathy with more slowly resolving sensory-predominant neuropathy—during repeated treatment for postoperative Crohn’s complications, in line with prior evidence from case series, systematic reviews, and population-based studies [13,17,18].

Metronidazole can cause a rapidly reversible cerebellar dentate encephalopathy and more slowly resolving, sensory-predominant peripheral neuropathy. This case underscores the importance of early recognition and immediate drug cessation for neurological recovery of such effects, while symptoms might require ongoing supportive management. Given the widespread use of metronidazole and potential risk modifiers, clinicians should proactively screen for neurologic symptoms during therapy and consider alternative anaerobic coverage at the earliest suspicion of toxicity.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

Conceptualization: YJM, SHoL, SHyL. Data curation: YJM. Formal analysis: YJM, SHyL. Investigation: YJM. Methodology: YJM, SHoL. Project administration: YJM. Resources: SHyL. Software: YJM. Supervision: SHyL. Validation: SHyL. Visualization: YJM. Writing-original draft: YJM. Writing-review & editing: YJM, SHoL, SHyL. All authors have read and approved the final manuscript.

References

1. Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: present status and future perspectives. World J Gastroenterol 2024;30:2068–80. 10.3748/wjg.v30.i15.2068. 38681984.
2. Lee SJ, Kim J, Lee KH, Lee JA, Kim CH, Ahn JY, et al. Frequency and risk factor analysis for metronidazole-associated neurologic adverse events. J Gen Intern Med 2024;39:912–20. 10.1007/s11606-023-08566-w. 38093026.
3. Kim E, Na DG, Kim EY, Kim JH, Son KR, Chang KH. MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR Am J Neuroradiol 2007;28:1652–8. 10.3174/ajnr.a0655. 17885234.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45. 10.1038/clpt.1981.154. 7249508.
5. Park HS, Han DS. Management of antibiotics-associated diarrhea. Korean J Gastroenterol 2009;54:5–12. 10.4166/kjg.2009.54.1.5. 19696544.
6. Sorensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. J Neurol 2020;267:1–13. 10.1007/s00415-018-9147-6.
7. Hobbs K, Stern-Nezer S, Buckwalter MS, Fischbein N, Finley Caulfield A. Metronidazole-induced encephalopathy: not always a reversible situation. Neurocrit Care 2015;22:429–36. 10.1007/s12028-014-0102-9. 25561434.
8. Bahn Y, Kim E, Park C, Park HC. Metronidazole induced encephalopathy in a patient with brain abscess. J Korean Neurosurg Soc 2010;48:301–4. 10.3340/jkns.2010.48.3.301. 21082066.
9. Hwang E, Chang SK, Lee SA, Choi JA. A case of metronidazole-induced encephalopathy: atypical involvement of the brain on MRI. Investig Magn Reson Imaging 2018;22:200–3. 10.13104/imri.2018.22.3.200.
10. Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol 2011;34:241–7. 10.1097/WNF.0b013e3182334b35. 21996645.
11. Sarna JR, Brownell AK, Furtado S. Cases: Reversible cerebellar syndrome caused by metronidazole. CMAJ 2009;181:611–3. 10.1503/cmaj.090591. 19752101.
12. Agarwal A, Kanekar S, Sabat S, Thamburaj K. Metronidazole-induced cerebellar toxicity. Neurol Int 2016;8:6365. 10.4081/ni.2016.6365. 27127600.
13. Arik N, Cengiz N, Bilge A. Metronidazole-induced encephalopathy in a uremic patient: a case report. Nephron 2001;89:108–9. 10.1159/000046052. 11528241.
14. Roy U, Panwar A, Pandit A, Das SK, Joshi B. Clinical and neuroradiological spectrum of metronidazole induced encephalopathy: our experience and the review of literature. J Clin Diagn Res 2016;10:OE01–9. 10.7860/jcdr/2016/19032.8054.
15. Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents 2018;51:319–25. 10.1016/j.ijantimicag.2017.08.033. 28887203.
16. Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. Can J Neurol Sci 2013;40:768–76. 10.1017/s0317167100015870. 24257215.
17. Gussago S, Poroli Bastone C, Celio D, Arigoni M, Quarenghi MC. Metronidazole and peripheral neuropathy: a report of two cases of (unusual) side effects. Cureus 2022;14e30889. 10.7759/cureus.30889. 36465791.
18. Huh SY, Kim JK, Kim MJ, Yoo BG, Kim KS, Lee JH. Reversible encephalopathy induced by metronidazole. J Korean Geriatr Soc 2008;12:176–8.
19. Daneman N, Cheng Y, Gomes T, Guan J, Mamdani MM, Saxena FE, et al. Metronidazole-associated neurologic events: a nested case-control study. Clin Infect Dis 2021;72:2095–100. 10.1093/cid/ciaa395. 32303736.

Article information Continued

Fig. 1.

Patient’s magnetic resonance imaging showing symmetric T2 hyperintensity of the cerebellar dentate nucleus.

Table 1.

Metronidazole treatment history in the present case

Admission/period Daily dose Duration (day) Route of administration Cumulative dose (mg)
Preoperative period (first admission) 500 mg×3/day (1,500 mg/day) 15 Intravenous 22,500
Postoperative period (first admission) 500 mg×3/day (1,500 mg/day) 7 Intravenous 10,500
Second admission 500 mg×3/day (1,500 mg/day) 16 Intravenous 24,000
Second admission 500 mg×3/day (1,500 mg/day) 6 Oral 9,000
Third admission (prior to dysarthria) 500 mg×3/day (1,500 mg/day) 4 Intravenous 4,500
Total 48 70,500